Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

AGEN

AGENUS INC

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1098972Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$114.0M
Net Income FY2025
$(3.0M)
EPS (Basic, as reported)
$0.00
Net Margin FY2025
-2.7%
ROE FY2025
1.1%
Total Equity
$(271.0M)
Shares Out
45M
Business description

AGENUS INC — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 23 → 114 +19.5% CAGR
Revenue2343371508829698156103114
Cost of revenue————(2)(3)(11)(3)0(1)
Research & development(95)(116)(125)(168)(143)(179)(187)(235)(156)(79)
General & administrative(33)(34)(37)(46)(59)(76)(81)(79)(72)(54)
Operating income(107)(104)(124)(70)(117)26(179)(160)(120)(20)
Interest expense(19)(31)————(64)(104)(120)(56)
Interest & investment income——————2630
Other income (expense), net(2)2(2)0(2)51306(2)
Pre-tax income(127)(121)—————(257)(232)(3)
Income tax expense0000000000
Net income(127)(121)(162)(112)(183)(29)(231)(257)(232)(3)
EPS — basic—————($0.11)($0.78)($0.69)($10.59)$0.00
EPS — diluted—————($0.11)($0.78)($0.69)($10.59)$0.00
Shares outstanding — basic (M)————00002130
Shares outstanding — diluted (M)————00002130

Showing the latest 10 of 17 fiscal years.

  • ⚑ Weighted-average shares changed ×1.43 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.